April 1, 2024Stroke

Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials

View Full Paper

Ask AI

Bookmark

Authors

HSHongfei SangArmy Medical University ZCZhihua CaoHubei University of Medicine JDJie DuChinese Academy of Medical Sciences & Peking Union Medical College

Discussion

Member takes

Implication

Randomized trial pooled analysis demonstrates comparable functional independence between tirofiban and alteplase in acute ischemic stroke, suggesting similar bridging efficacy.

Key Points

Functional independence occurred in 60.2% of tirofiban patients compared with 46.6% receiving alteplase, demonstrating comparable bridging efficacy before endovascular treatment.
Post hoc analysis using data from 2 multicenter, randomized trials evaluated 216 acute ischemic stroke patients with large vessel occlusion within 4.5 hours from symptom onset.
Preliminary findings show tirofiban does not increase symptomatic intracranial hemorrhage or mortality, highlighting its potential utility pending randomized trial confirmation.

Cite This Study

Sang et al. (2024) studied this question.

synapsesocial.com/papers/68e70edbb6db643587687ba0 https://doi.org/10.1161/strokeaha.123.044562

View Full Paper

Ask AI

Bookmark

April 1, 2024Stroke

Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials

View Full Paper

Ask AI

Bookmark

Authors

HSHongfei SangArmy Medical University ZCZhihua CaoHubei University of Medicine JDJie DuChinese Academy of Medical Sciences & Peking Union Medical College

Discussion

Member takes

Implication

Randomized trial pooled analysis demonstrates comparable functional independence between tirofiban and alteplase in acute ischemic stroke, suggesting similar bridging efficacy.

Key Points

Functional independence occurred in 60.2% of tirofiban patients compared with 46.6% receiving alteplase, demonstrating comparable bridging efficacy before endovascular treatment.
Post hoc analysis using data from 2 multicenter, randomized trials evaluated 216 acute ischemic stroke patients with large vessel occlusion within 4.5 hours from symptom onset.
Preliminary findings show tirofiban does not increase symptomatic intracranial hemorrhage or mortality, highlighting its potential utility pending randomized trial confirmation.

Cite This Study

Sang et al. (2024) studied this question.

synapsesocial.com/papers/68e70edbb6db643587687ba0 https://doi.org/10.1161/strokeaha.123.044562

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark